Compare Stocks

Date Range: 

 3MStrykerBecton, Dickinson andBoston ScientificDexCom
SymbolNYSE:MMMNYSE:SYKNYSE:BDXNYSE:BSXNASDAQ:DXCM
Price Information
Current Price$182.66$276.11$262.67$44.90$565.13
50-Day Moving Average$196.34$266.93$250.91$44.32$499.14
52-Week Low$156.13$196.09$219.50$32.99$305.63
52-Week High$208.95$281.16$267.37$46.28$567.81
MarketRank™
Overall Score2.52.42.42.12.4
Analysis Score2.02.31.21.52.4
Community Score4.44.54.34.75.0
Dividend Score2.51.74.20.00.0
Ownership Score2.52.52.52.52.5
Earnings & Valuation Score1.31.30.01.91.9
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyBuy
Consensus Price Target$198.09$286.43$273.63$49.13$507.47
% Upside from Price Target8.45% upside3.74% upside4.17% upside9.43% upside-10.20% downside
Trade Information
Market Cap$105.69 billion$104.12 billion$75.44 billion$63.93 billion$54.68 billion
Beta0.960.980.760.880.77
Average Volume2,425,8351,164,8871,355,5657,844,357766,148
Sales & Book Value
Annual Revenue$32.18 billion$14.35 billion$17.12 billion$9.91 billion$1.93 billion
Price / Sales3.287.264.416.4528.38
Cashflow$12.01 per share$9.76 per share$18.04 per share$2.16 per share$3.96 per share
Price / Cash15.2128.2814.5620.77142.74
Book Value$22.42 per share$34.82 per share$81.98 per share$10.81 per share$19.02 per share
Price / Book8.157.933.204.1529.71
Profitability
Net Income$5.38 billion$1.60 billion$874 million$-82,000,000.00$493.60 million
EPS$8.74$7.43$10.20$0.96$3.10
Trailing P/E Ratio17.9650.5741.24136.06107.64
Forward P/E Ratio16.7726.2721.2924.01167.20
P/E Growth1.923.082.422.9314.59
Net Margins17.13%12.82%9.72%4.56%24.45%
Return on Equity (ROE)44.72%26.08%16.26%12.67%16.17%
Return on Assets (ROA)12.65%10.41%7.26%6.41%6.87%
Dividend
Annual Payout$5.92$2.52$3.32N/AN/A
Dividend Yield3.24%0.91%1.26%N/AN/A
Three-Year Dividend Growth25.11%34.96%8.84%N/AN/A
Payout Ratio67.73%33.92%32.55%N/AN/A
Years of Consecutive Dividend GrowthN/AN/A50 YearsN/AN/A
Debt
Debt-to-Equity Ratio1.12%0.92%0.65%0.55%0.86%
Current Ratio1.73%2.12%1.23%1.66%5.78%
Quick Ratio1.22%1.32%0.85%1.31%5.25%
Ownership Information
Institutional Ownership Percentage66.82%72.58%84.25%89.80%96.29%
Insider Ownership Percentage0.34%6.70%0.76%0.71%0.52%
Miscellaneous
Employees94,98743,00065,0002,0206,400
Shares Outstanding578.64 million377.10 million287.19 million1.42 billion96.75 million
Next Earnings Date10/26/2021 (Confirmed)11/4/2021 (Estimated)11/4/2021 (Estimated)10/27/2021 (Estimated)10/26/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Piper Sandler raises price target on DexCom on growth of continuous glucose monitoringPiper Sandler raises price target on DexCom on growth of continuous glucose monitoring
seekingalpha.com - September 16 at 3:13 PM
DexCom (NASDAQ:DXCM) Price Target Increased to $650.00 by Analysts at Piper SandlerDexCom (NASDAQ:DXCM) Price Target Increased to $650.00 by Analysts at Piper Sandler
americanbankingnews.com - September 16 at 10:00 AM
DexCom (NASDAQ:DXCM) PT Raised to $650.00 at Piper SandlerDexCom (NASDAQ:DXCM) PT Raised to $650.00 at Piper Sandler
marketbeat.com - September 16 at 7:31 AM
2 Sizzling Hot Stocks to Buy Right Now - Motley Fool2 Sizzling Hot Stocks to Buy Right Now - Motley Fool
fool.com - September 15 at 3:05 PM
Notable Dexcom Insider Makes $3.06 Million Sale - BenzingaNotable Dexcom Insider Makes $3.06 Million Sale - Benzinga
benzinga.com - September 14 at 6:27 PM
Dexcom Fights Abbotts Bid To Invalidate Its Diabetes Tech IP - Law360Dexcom Fights Abbott's Bid To Invalidate Its Diabetes Tech IP - Law360
law360.com - September 14 at 6:27 PM
Dexcoms (DXCM) G6 CGM Under NIHB Program to Aid More Patients - NasdaqDexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients - Nasdaq
nasdaq.com - September 14 at 6:27 PM
Dexcoms (DXCM) G6 CGM Under NIHB Program to Aid More PatientsDexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients
finance.yahoo.com - September 14 at 6:26 PM
Insights on the Automated Insulin Delivery System Global Market to 2026 - Featuring Biocon, Dexcom and Digital Medics Among Others - Yahoo FinanceInsights on the Automated Insulin Delivery System Global Market to 2026 - Featuring Biocon, Dexcom and Digital Medics Among Others - Yahoo Finance
finance.yahoo.com - September 14 at 7:58 AM
Insider Selling: DexCom, Inc. (NASDAQ:DXCM) CFO Sells 407 Shares of StockInsider Selling: DexCom, Inc. (NASDAQ:DXCM) CFO Sells 407 Shares of Stock
americanbankingnews.com - September 13 at 10:42 PM
Insider Selling: DexCom, Inc. (NASDAQ:DXCM) Insider Sells 5,597 Shares of StockInsider Selling: DexCom, Inc. (NASDAQ:DXCM) Insider Sells 5,597 Shares of Stock
americanbankingnews.com - September 13 at 10:10 PM
Shelly Ramasamy Selvaraj Sells 2,223 Shares of DexCom, Inc. (NASDAQ:DXCM) StockShelly Ramasamy Selvaraj Sells 2,223 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock
americanbankingnews.com - September 13 at 10:10 PM
Kevin R. Sayer Sells 3,017 Shares of DexCom, Inc. (NASDAQ:DXCM) StockKevin R. Sayer Sells 3,017 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock
americanbankingnews.com - September 13 at 10:10 PM
Form 4 DEXCOM INC For: Sep 09 Filed by: Balo Andrew K - StreetInsider.comForm 4 DEXCOM INC For: Sep 09 Filed by: Balo Andrew K - StreetInsider.com
streetinsider.com - September 13 at 9:57 PM
The Chief Operating Officer of DexCom, Inc. (NASDAQ:DXCM), Quentin Blackford, Just Sold 98% Of Their Holding - NasdaqThe Chief Operating Officer of DexCom, Inc. (NASDAQ:DXCM), Quentin Blackford, Just Sold 98% Of Their Holding - Nasdaq
nasdaq.com - September 13 at 9:56 PM
iRhythm gets back on beat, tapping former Dexcom exec as CEO - FierceBiotechiRhythm gets back on beat, tapping former Dexcom exec as CEO - FierceBiotech
fiercebiotech.com - September 13 at 4:56 PM
Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy - Business WireNon-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy - Business Wire
businesswire.com - September 13 at 4:56 PM
Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin TherapyNon-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy
finance.yahoo.com - September 13 at 4:56 PM
Notable Dexcom Insider Makes $10.22 Million Sale - BenzingaNotable Dexcom Insider Makes $10.22 Million Sale - Benzinga
benzinga.com - September 10 at 10:05 PM
People in the News: New Appointments at Cue Health, Berkeley Lights, LGC, More - GenomeWebPeople in the News: New Appointments at Cue Health, Berkeley Lights, LGC, More - GenomeWeb
genomeweb.com - September 10 at 5:04 PM
DexCom (NASDAQ:DXCM) Sets New 52-Week High at $555.09DexCom (NASDAQ:DXCM) Sets New 52-Week High at $555.09
americanbankingnews.com - September 7 at 10:32 AM
GlucoModicum announces the appointment of Peter Gerhardsson as a Senior Advisor - Yahoo FinanceGlucoModicum announces the appointment of Peter Gerhardsson as a Senior Advisor - Yahoo Finance
finance.yahoo.com - September 7 at 3:03 AM
The 10 highest-paid CEOs in San Diego in 2020 - The San Diego Union-TribuneThe 10 highest-paid CEOs in San Diego in 2020 - The San Diego Union-Tribune
sandiegouniontribune.com - September 5 at 11:16 AM
3 Growth Stocks Thatll Make You Richer By 20243 Growth Stocks That'll Make You Richer By 2024
finance.yahoo.com - September 5 at 6:10 AM
$0.62 Earnings Per Share Expected for DexCom, Inc. (NASDAQ:DXCM) This Quarter$0.62 Earnings Per Share Expected for DexCom, Inc. (NASDAQ:DXCM) This Quarter
americanbankingnews.com - September 3 at 10:24 AM
$0.62 EPS Expected for DexCom, Inc. (NASDAQ:DXCM) This Quarter$0.62 EPS Expected for DexCom, Inc. (NASDAQ:DXCM) This Quarter
americanbankingnews.com - September 3 at 10:24 AM
DexCom Beats Views, Raises Guidance, But Shares Are DownDexCom Beats Views, Raises Guidance, But Shares Are Down
marketbeat.com - June 3 at 6:00 AM
DateCompanyBrokerageAction
9/16/2021DexComPiper Sandler
Boost Price Target
9/14/2021StrykerRaymond James
Initiated Coverage
8/6/2021Becton, Dickinson andSVB Leerink
Lower Price Target
8/6/2021Becton, Dickinson andJPMorgan Chase & Co.
Downgrade
8/2/2021DexComMorgan Stanley
Boost Price Target
7/30/2021DexComStephens
Boost Price Target
7/30/2021DexComWells Fargo & Company
Boost Price Target
7/30/2021DexComSVB Leerink
Boost Price Target
7/30/2021DexComOppenheimer
Boost Price Target
7/30/2021DexComCanaccord Genuity
Boost Price Target
7/30/2021DexComRaymond James
Boost Price Target
7/30/2021DexComRobert W. Baird
Boost Price Target
7/30/2021DexComPiper Sandler
Boost Price Target
7/29/2021StrykerArgus
Boost Price Target
7/28/20213MMorgan Stanley
Boost Price Target
7/28/20213MArgus
Boost Price Target
7/28/20213MDeutsche Bank Aktiengesellschaft
Boost Price Target
7/28/2021StrykerTruist Securities
Boost Price Target
7/28/2021StrykerCanaccord Genuity
Boost Price Target
7/28/2021StrykerMorgan Stanley
Boost Price Target
7/28/2021StrykerTruist
Boost Price Target
7/28/2021StrykerSVB Leerink
Boost Price Target
7/28/2021StrykerCredit Suisse Group
Boost Price Target
7/28/2021StrykerOppenheimer
Boost Price Target
7/28/2021StrykerNorthland Securities
Upgrade
7/28/2021StrykerNeedham & Company LLC
Reiterated Rating
7/28/2021StrykerRobert W. Baird
Boost Price Target
7/28/2021StrykerCitigroup
Boost Price Target
7/28/2021StrykerPiper Sandler
Boost Price Target
7/28/2021Boston ScientificCredit Suisse Group
Boost Price Target
7/28/2021Boston ScientificRaymond James
Boost Price Target
7/28/2021Boston ScientificMorgan Stanley
Boost Price Target
7/21/2021DexComCowen
Lower Price Target
7/20/2021StrykerSVB Leerink
Reiterated Rating
7/20/2021Becton, Dickinson andSVB Leerink
Reiterated Rating
7/15/2021Boston ScientificNeedham & Company LLC
Set Price Target
7/14/20213MDeutsche Bank Aktiengesellschaft
Lower Price Target
7/12/20213MWolfe Research
Downgrade
7/6/20213MCredit Suisse Group
Downgrade
7/1/2021DexComStephens
Reiterated Rating
6/28/2021StrykerCredit Suisse Group
Reiterated Rating
6/7/2021Boston ScientificArgus
Boost Price Target
6/1/2021StrykerEvercore ISI
Upgrade
5/28/2021DexComWells Fargo & Company
Upgrade
5/26/2021Boston ScientificNeedham & Company LLC
Downgrade
5/24/2021StrykerBarclays
Initiated Coverage
5/24/2021Becton, Dickinson andBarclays
Initiated Coverage
5/24/2021Boston ScientificBarclays
Initiated Coverage
5/24/2021DexComBarclays
Initiated Coverage
5/7/2021Becton, Dickinson andSVB Leerink
Lower Price Target
4/30/2021DexComCitigroup
Boost Price Target
4/30/2021DexComCanaccord Genuity
Boost Price Target
4/30/2021DexComRaymond James
Boost Price Target
4/29/2021Boston ScientificTruist
Boost Price Target
4/29/2021Boston ScientificCanaccord Genuity
Boost Price Target
4/29/2021Boston ScientificMorgan Stanley
Boost Price Target
4/29/2021Boston ScientificWells Fargo & Company
Boost Price Target
4/29/2021Boston ScientificDeutsche Bank Aktiengesellschaft
Boost Price Target
4/28/20213MCredit Suisse Group
Lower Price Target
4/28/20213MRoyal Bank of Canada
Boost Price Target
4/28/20213MDeutsche Bank Aktiengesellschaft
Boost Price Target
4/28/2021StrykerTruist Securities
Boost Price Target
4/28/2021StrykerOppenheimer
Boost Price Target
4/28/2021StrykerTruist
Boost Price Target
4/28/2021StrykerCitigroup
Boost Price Target
4/28/2021StrykerCanaccord Genuity
Boost Price Target
4/28/2021StrykerMorgan Stanley
Boost Price Target
4/28/2021StrykerWells Fargo & Company
Boost Price Target
4/15/2021Boston ScientificAtlantic Securities
Initiated Coverage
4/15/2021DexComAtlantic Securities
Initiated Coverage
4/12/20213MMorgan Stanley
Boost Price Target
4/6/20213MBarclays
Boost Price Target
3/23/20213MCredit Suisse Group
Boost Price Target
2/12/2021Boston ScientificNeedham & Company LLC
Boost Price Target
2/12/2021DexComCitigroup
Lower Price Target
2/12/2021DexComOppenheimer
Boost Price Target
2/12/2021DexComMorgan Stanley
Boost Price Target
2/12/2021DexComRaymond James
Boost Price Target
2/5/2021Becton, Dickinson andCitigroup
Boost Price Target
2/4/2021Becton, Dickinson andPiper Sandler
Boost Price Target
2/4/2021Boston ScientificRaymond James
Boost Price Target
2/3/20213MArgus
Upgrade
2/3/2021Boston ScientificPiper Sandler
Boost Price Target
2/1/2021Boston ScientificDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/29/2021Becton, Dickinson andRaymond James
Boost Price Target
1/29/2021DexComPiper Sandler
Boost Price Target
1/27/20213MCitigroup
Boost Price Target
1/27/20213MCredit Suisse Group
Lower Price Target
1/27/20213MJPMorgan Chase & Co.
Upgrade
1/24/20213MRoyal Bank of Canada
Reiterated Rating
1/12/20213MMorgan Stanley
Boost Price Target
1/7/20213MBank of America
Downgrade
1/6/2021DexComUBS Group
Upgrade
12/15/2020Becton, Dickinson andThe Goldman Sachs Group
Downgrade
12/15/2020Becton, Dickinson andWells Fargo & Company
Downgrade
12/15/2020Becton, Dickinson andMorgan Stanley
Upgrade
12/15/2020Boston ScientificMorgan Stanley
Boost Price Target
12/15/2020Boston ScientificThe Goldman Sachs Group
Downgrade
12/15/2020DexComMorgan Stanley
Boost Price Target
12/8/2020Boston ScientificBTIG Research
Reiterated Rating
11/18/2020Boston ScientificTruist
Lower Price Target
11/18/2020Boston ScientificSmith Barney Citigroup
Lower Price Target
11/18/2020Boston ScientificWells Fargo & Company
Lower Price Target
11/18/2020Boston ScientificMorgan Stanley
Lower Price Target
11/17/2020Boston ScientificNeedham & Company LLC
Lower Price Target
11/6/2020Becton, Dickinson andMorgan Stanley
Lower Price Target
10/28/20203MMorgan Stanley
Boost Price Target
10/27/20203MWilliam Blair
Reiterated Rating
10/13/20203MMorgan Stanley
Boost Price Target
10/12/2020Becton, Dickinson andRaymond James
Lower Price Target
10/7/20203MJPMorgan Chase & Co.
Boost Price Target
10/7/20203MGordon Haskett
Upgrade
10/2/2020Becton, Dickinson andThe Goldman Sachs Group
Upgrade
9/16/20203MCredit Suisse Group
Boost Price Target
8/27/2020Becton, Dickinson andMorgan Stanley
Lower Price Target
8/10/2020Becton, Dickinson andUBS Group
Boost Price Target
8/10/2020Becton, Dickinson andMorgan Stanley
Boost Price Target
8/7/2020Becton, Dickinson andRaymond James
Boost Price Target
7/15/2020Becton, Dickinson andSVB Leerink
Boost Price Target
7/9/2020Becton, Dickinson andBarclays
Upgrade
7/2/2020Becton, Dickinson andWilliam Blair
Reiterated Rating
6/25/2020Becton, Dickinson andMorgan Stanley
Lower Price Target
6/25/2020Becton, Dickinson andRaymond James
Lower Price Target
5/31/2020Becton, Dickinson andThe Goldman Sachs Group
Initiated Coverage
5/14/2020Becton, Dickinson andPiper Sandler
Boost Price Target
(Data available from 9/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at con[email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.